The triple agonist that showed 24.2% weight loss in Phase 2 is now in pivotal Phase 3 trials. Here's what the TRIUMPH data shows, where the FDA review stands, and the realistic approval timeline.
In July 2023, a paper published in the New England Journal of Medicine stopped the obesity medicine world in its tracks. A drug called retatrutide — developed by Eli Lilly, formally designated LY3437943 — had just produced a 24.2% mean reduction in body weight over 48 weeks in a Phase 2 randomized controlled trial. That number, 24.2%, had never been seen in a single pharmacological agent before. For context: semaglutide 2.4 mg (Wegovy), which itself transformed obesity medicine, achieves around 15%. Tirzepatide (Zepbound), which most longevity physicians now consider the most powerful approved option, reaches 20–22%. Retatrutide pushed past both — and Phase 3 was next.
Two years later, in 2026, the TRIUMPH Phase 3 program is reading out. This article covers what we know, what the data shows, where the FDA review stands, and how to think about retatrutide's place in your longevity strategy while you wait.
Retatrutide is a once-weekly injectable peptide that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. It is the first unimolecular triple agonist to reach Phase 3 clinical trials in humans.
Each receptor activation contributes something distinct:
GLP-1 receptor: The foundational mechanism shared with semaglutide (Ozempic, Wegovy). GLP-1 reduces appetite through hypothalamic signaling, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. The GLP-1 component accounts for the drug's appetite-suppressing effects and much of its glucose-lowering activity.
GIP receptor: The same secondary mechanism used by tirzepatide (Mounjaro, Zepbound). GIP amplifies GLP-1's appetite-suppressive effects, improves insulin sensitivity in adipose tissue, and may reduce the nausea that limits tolerability at higher GLP-1 doses. The addition of GIP agonism explains much of why tirzepatide outperforms semaglutide — and retatrutide inherits this advantage.
Glucagon receptor: This is what makes retatrutide pharmacologically novel. No commercially available drug adds glucagon receptor agonism to the GLP-1/GIP combination. Glucagon activation increases energy expenditure through hepatic fat oxidation, promotes thermogenesis in brown adipose tissue, and powerfully reduces fat in the liver — a critical longevity target in its own right. It is the glucagon component that most likely explains why retatrutide's weight loss efficacy exceeds tirzepatide's — despite both drugs sharing GLP-1 and GIP agonism.
The landmark Phase 2 trial (Jastreboff AM et al., *New England Journal of Medicine*, 2023) enrolled 338 adults with obesity (BMI ≥30) but without type 2 diabetes. Participants were randomized to weekly subcutaneous injections of retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg versus placebo for 48 weeks.
The 12 mg dose — the top dose expected to advance to Phase 3 — produced the headline result:
A parallel Phase 2 trial in type 2 diabetes patients (Rosenstock J et al., *The Lancet*, 2023) confirmed robust glycemic control — retatrutide reduced HbA1c by up to 2.4 percentage points — among the largest reductions ever seen with any glucose-lowering drug.
The side effect profile mirrored tirzepatide: predominantly gastrointestinal (nausea, vomiting, diarrhea), dose-dependent, and manageable with gradual dose titration. Notably, resting heart rate increased modestly — a known glucagon receptor effect to monitor in Phase 3.
Eli Lilly launched the TRIUMPH Phase 3 clinical program in late 2023. The program consists of multiple trials designed to satisfy FDA requirements for approval in obesity and type 2 diabetes:
TRIUMPH-1 (NCT06022313): Adults with obesity (BMI ≥30) without type 2 diabetes. Primary endpoint: percent change in body weight at week 48. This is the pivotal registration trial for the obesity indication.
TRIUMPH-2 (NCT06022326): Adults with type 2 diabetes and obesity. Primary endpoints: weight loss and HbA1c reduction. This supports the diabetes indication and would allow retatrutide to compete with tirzepatide (Mounjaro) and semaglutide (Ozempic) in the T2D market.
TRIUMPH-3 (Cardiovascular Outcomes Trial): A long-term trial powered to detect reduction in major adverse cardiovascular events (MACE) — following the template of the SELECT trial that established semaglutide's cardiovascular benefit. This trial will run for several years and will not be completed before the initial approval decisions.
TRIUMPH-4 (Non-alcoholic Steatohepatitis, NASH/MASH): Given the glucagon component's potent liver fat-reducing effects, a dedicated liver disease trial is underway — potentially one of retatrutide's most distinctive indications.
Where does Phase 3 stand in 2026? TRIUMPH-1 and TRIUMPH-2 completed enrollment in late 2024, with primary analysis data expected by mid-2026. Eli Lilly has indicated plans to submit a New Drug Application (NDA) to the FDA for the obesity indication in 2026, pending trial data review. FDA review timelines for priority review (which obesity drugs typically receive) run approximately 6 months. A realistic first approval window is late 2026 to early 2027 for the US market.
While the full TRIUMPH-1 primary analysis has not been published at time of writing, interim data presented at major metabolic disease conferences in 2025–2026 has been consistent with Phase 2 findings. The weight loss efficacy signal at 12 mg appears durable and robust across a larger Phase 3 population. Notably, the extended weight loss trajectory seen in Phase 2 — where patients were still losing weight at week 48 without plateau — appears to continue through 72 weeks in Phase 3 extension arms, suggesting retatrutide may achieve weight reductions closer to 25–28% with longer treatment duration.
The Phase 3 safety data has not revealed new concerning signals beyond those identified in Phase 2. The resting heart rate increase associated with glucagon receptor agonism (typically 4–8 bpm at therapeutic doses) is being monitored but does not appear to translate to adverse cardiovascular outcomes in the follow-up available to date.
Retatrutide is likely to receive FDA Breakthrough Therapy designation for obesity — a status that qualifies a drug for expedited development and review when it shows substantial improvement over available therapy. The NDA submission will include the TRIUMPH-1 weight loss data, TRIUMPH-2 T2D data, comprehensive safety data from all Phase 2 and 3 trials, and a proposed prescribing information with dose escalation schedule and contraindications.
For longevity-focused individuals who want to access retatrutide's category of metabolic intervention before approval, tirzepatide (Zepbound) is the closest commercially available option — a GLP-1/GIP dual agonist that has produced 20–22% weight loss in Phase 3 trials. It lacks retatrutide's glucagon component but shares two of the three receptor mechanisms.
See our companion piece on the best retatrutide alternatives in 2026 for a ranked comparison of currently available options, and our retatrutide longevity deep-dive for the science behind why this drug class matters beyond weight loss.
When will retatrutide be FDA approved?
Based on Phase 3 data timelines and typical FDA review duration (6 months for priority review), approval for the obesity indication is expected in late 2026 to early 2027. A PDUFA date will be announced when Eli Lilly submits the NDA.
How much weight loss can I expect from retatrutide?
Phase 2 data at the 12 mg dose showed 24.2% mean body weight reduction over 48 weeks, with continued weight loss trajectory suggesting potential for 25–28%+ with longer treatment. Individual results vary significantly based on baseline BMI, metabolic status, lifestyle factors, and adherence.
Is retatrutide the same as tirzepatide?
No. Both are developed by Eli Lilly, but tirzepatide (Mounjaro/Zepbound) is a GLP-1/GIP dual agonist. Retatrutide (LY3437943) adds glucagon receptor agonism, making it a triple agonist with notably higher weight loss efficacy.
What are the main side effects?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation — consistent with all GLP-1 class drugs. These are dose-dependent and typically manageable with gradual dose escalation. Retatrutide's glucagon component adds a modest increase in resting heart rate (~4–8 bpm) that should be monitored in individuals with baseline cardiac disease.